Relative efficacy and potency of β-adrenoceptor agonists for generating cAMP in human lymphocytes

Chest

Volumn 109, Issue 1, 1996, Pages 194-200

  MacGregor, Drew A ^a   Prielipp, Richard C ^a   Butterworth IV, John F ^a   James, Robert L ^a   Royster, Roger L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

dobutamine; dopexamine; epinephrine; inotropes; isoproterenol; lymphocyte s; adrenergic agonists

Indexed keywords

ADRENALIN; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; DOBUTAMINE; DOPAMINE; DOPEXAMINE; ISOPRENALINE; NORADRENALIN;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030047049     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.1.194     Document Type: Article

References (49)

1. Breslow MJ, Ligier B. Hyperadrenergic states. Crit Care Med 1991; 19:1566-79
2. McDevitt DG. In vivo studies on the function of cardiac beta-adrenoceptors in man. Eur Heart J 1989; 10(supp) B):22-8
3. Bristow MR, Hershberger RE, Port JD, et al. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82(suppl 2):112-25
4. Royster RL. Intraoperative administration of inotropes in cardiac surgery patients. J Cardiothorac Anesth 1990; 4:17S-28S
5. Motulsky HJ, Insel PA. Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations. N Engl J Med 1982; 307:18-29
6. Chatterjee K, De Marco T. Central and peripheral adrenergic receptor agonists in heart failure. Eur Heart J 1989; 10(suppl B):55-63
7. 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 1989; 10(suppl B):29-37
8. Bristow MR, Port JD, Hershberger RE, et al. The β-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur Heart J 1989; 10(suppl B):45-54
9. Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and lieta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297-309
10. Prielipp RC, Butterworth JF IV, Royster RL, et al. Dobutamine antagonizes cAMP production by epinephrine in human lymphocytes [abstract]. Anesth Analg 1993; 76:S334
11. Abernethy WB, Butterworth JF IV, Prielipp RC, et al. Calcium entry attenuates adenylyl cyclase activity: a possible mechanism for calcium-induced catecholamine resistance. Chest 1995; 107:1420-25
12. Hull CJ. Pharmacokinetics for anesthesia. Oxford: Butterworth-Heinemann, 1991; 87-90
13. The mixed procedure. In: SAS technical report. Cary, NC: SAS Institute, 1992; 289-366
14. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6:65-70
15. Waelbroeck M, Tatou C, Delhaye M, et al. The human heart beta-adrenergic receptors: II. Coupling of β2-adrenergic receptors with the adenylate cyclase system. Mol Pharmacol 1983; 24:174-82
16. Kojima S, Wu ST, Parmley WW, et al. Relationship between intracellular calcium and oxygen consumption: effects of perfusion pressure, extracellular calcium, dobutamine, and nifedipine. Am Heart J 1994; 127:386-91
17. Wikman-Coffelt J, Wu ST, Parmley WW. Intracellular endocardial calcium and myocardial function in rat hearts. Cell Calcium 1991; 12:39-50
18. Swynghedauw B, Delcayre C, Cheav SL, et al. Biological basis of diastolic dysfunction of the hypertensive heart (review). Eur Heart J 1992; 13(suppl D):2-8
19. Katz AM. Inotropic and lusitropic abnormalities in heart failure. Eur Heart J 1990; 11(suppl A):27-31
20. Morgan JP, Erny RE, Allen PD, et al. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 1990; 81(suppl 2):21-32
21. 125I]iodocyanopindolol binding. Circ Res 1983; 53:752-58
22. 2-adrenoceptors in the human heart. Eur Heart J 1989; 10(suppl B):11-21
23. Lands AM, Luduena FP, Buzzo HJ. Differentiation of receptors responsive to isoproterenol. Life Sci 1967; 6:2241-49
24. Åblad B, Carlsson B, Carlsson E, et al. Cardiac effects of β-adrenergic receptor antagonists. Adv Cardiol 1974; 12:290-302
25. 2-adrenergic receptors. Mol Pharmacol 1983; 24:169-73
26. 2-adrenoceptors. Eur Heart J 1989; 10(suppl B):38-44
27. Stiles GL, Taylor S, Lefkowitz RJ. Human cardiac beta-adrenoceptors: subtype heterogeneity delineated by direct radioligand binding. Life Sci 1983; 330:467-73
28. Buxton BF, Jones CR, Molenaar P, et al. Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues. Br J Pharmacol 1987; 92:299-310
29. 2 subtypes by radioligand binding. Br J Pharmacol 1983; 80:711-17
30. Lathers CM, Levin RM, Spivey WH. Regional distribution of myocardial β-adrenoceptors in the cat. Eur J Pharmacol 1986; 130:111-17
31. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 1986; 8:1235-42
32. Royster RL, Butterworth JF IV, Prough DS, et al. Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting. Anesth Analg 1991; 72:729-36
33. Brodde OE, Wang XL. β-Adrenoceptor changes in blood lymphocytes and altered drug responsiveness. Ann Clin Res 1988; 20:311-23
34. Brodde OE, Michel MC, Gordon EP, et al. Beta-adrenoceptor regulation in the human heart: can it be monitored in circulating lymphocytes? Eur Heart J 1989; 10(suppl B):2-10
35. Brodde OE, Beckeringh JJ, Michel MC. Human heart β-adrenoceptors: a fair comparison with lymphocyte β-adrenoceptors? Trends Pharmacol Sci 1987; 8:403-07
36. Bristow MR, Larrabee P, Muller-Beckmann B, et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 1992; 70(suppl 1):S105-1.3
37. Singh M, Notterman DA, Metakis L. Tumor necrosis factor produces homologous desensitization of lymphocyte beta 2-adrenergic responses. Circ Shock 1993; 39:275-78
38. Silverman HJ, Lee NH, el-Fakahany EE. Effects of canine endotoxin shock on lymphocytic beta-adrenergic receptors. Circ Shock 1990; 32:293-306
39. Johnson JA. Racial differences in lymphocyte beta-receptor sensitivity to propranolol. Life Sci 1993; 53:297-304
40. Stein M, O'Malley K, Kilfeather S. Ethnic differences in cyclic AMP accumulation: effect on alpha 2, beta 2, and prostanoid receptor responses. Clin Phannacol Ther 1990; 47:360-65
41. Halper JP, Mann JJ, Weksler ME, et al. Beta adrenergic receptors and cyclic AMP levels in intact human lymphocytes: effects of age and gender. Life Sci 1984; 35:855-63
42. Gietzen DW, Goodman TA, Weiler PG, et al. Beta receptor density in human lymphocyte membranes: changing with aging? J Gerontol 1991; 46:B130-34
43. Davis PB, Byard PJ. Beta-adrenergic responses and airway reactivity in healthy adults. Mech Ageing Dev 1990; 54:29-42
44. Schwinn DA, Leone BJ, Spahn DR, et al. Desensitization of myocardial β-adrenergic receptors during cardiopulmonary bypass: evidence for early uncoupling and late downregulation. Circulation 1991; 84:2559-67
45. Smiley RM, Vulliemoz Y. Cardiac surgery causes desensitization of the beta-adrenergic receptor system of human lymphocytes. Anesth Analg 1992; 74:212-18
46. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989; 35:295-303
47. Butterworth JF IV, Brownlow RC, Leith JP, et al. Bupivacaine inhibits cyclic-3′,5′-adenosine monophosphate production: a possible contributing factor to cardiovascular toxicity. Anesthesiology 1993; 79:88-95
48. Allolio B, Ehses W, Steffen HM, et al. Reduced lymphocyte beta 2-adrenoceptor density and impaired diastolic left ventricular function in patients with glucocorticoid deficiency. Clin Endocrinol 1994; 40:769-75
49. Port JD, Gilbert EM, Larrabee P, et al. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation 1990; 81:929-38